Helping your patients understand the importance of a retinal health check.
Glaucoma is the second leading cause of blindness in the world, according to the World Health Organization.
Join us in raising awareness of the importance of frequent vision screenings and retinal health checks.
Almost 3 million people ages 40 and older have glaucoma, yet only half know they have it. Even more alarming is that the number of people with glaucoma is projected to increase in the next few decades to more than 4 million by 2030 and more than 6 million by 2050. NIH-NEHEP.

Help your patients understand what glaucoma looks like
Glaucoma often has no symptoms. In fact, half of all people with glaucoma don’t know they have it, and if it is not detected and treated, they can lose their sight.

Who is affected by Glaucoma? 1

Blindness from glaucoma is 6 to 8 times more common in African Americans than Caucasians.
African Americans are 15 times more likely to be visually impaired from glaucoma than Caucasians.
The most common form, open-angle glaucoma, accounts for 19% of all blindness among African Americans compared to 6% in Caucasians.
Other high-risk groups include: people over 60, family members of those already diagnosed, diabetics, and people who are severely nearsighted.
Listen to Mark T. Dunbar OD, FAAO, Director of Optometric Services at Bascom Palmer Eye Institute, University of Miami, share the benefits he sees by using CIRRUS™ HD-OCT from ZEISS to manage his glaucoma patients. Dr. Dunbar focuses in on two important questions: 1. Can we rely on the OCT to help diagnose early glaucoma and 2. Can the OCT help detect early progression.
Optimize your patient care and management.
Must-have technology for your practice.

Optical Coherence Tomography (OCT)
CIRRUS HD-OCT with AngioPlex allows for the visualization of both vascular and structural information from a single, non-invasive scan, making visualization of microvasculature of the retina a routine part of everyday care.

Ultra-Widefield Fundus Imaging
CLARUS™ 500 from ZEISS, next generation ultra-widefield fundus imaging is the first system to provide true color and clarity in an ultra-wide field of view – from the posterior pole to the far periphery.

Accelerate your clinical flow
Reaching new heights with the gold standard in perimetry, the HFA3 with Liquid Trial Lens, SmartTouch and Guided Progression Analysis™ provides a streamlined and faster workflow.

Streamline your decision-making
Integrate individual data sets into a single visualization to help guide your assessments by spotlighting changes in progression that could impact disease management.
1 Glaucoma Research Foundation https://www.glaucoma.org/glaucoma/glaucoma-facts-and-stats.php